Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Gaurab Bhaduri, Shilanjan Roy, Anchin Kalia et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the risk of depression in patients receiving semaglutide for Type 2 diabetes and obesity. The analysis included various study types and found a pooled risk ratio for depression of 1.25 (95% CI: 0.95-1.65). However, no statistically significant differences were observed between semaglutide and comparator groups.
Key findings
- Pooled risk ratio for depression was 1.25 (95% CI: 0.95-1.65).
- Pooled risk ratio for anxiety was 1.22 (95% CI: 0.93-1.60).
- Pooled risk ratio for suicidal ideation/attempt was 1.20 (95% CI: 0.90-1.62).
- No statistically significant differences were found between semaglutide and comparator groups.
Why it matters
Understanding the neuropsychiatric effects of GLP-1 receptor agonists like semaglutide is crucial for clinicians managing patients with Type 2 diabetes and obesity, as mental health can significantly impact treatment adherence and overall health outcomes.
What to keep in mind
The certainty of evidence was limited by substantial heterogeneity, risk of bias, and reliance on heterogeneous data sources.